Senseonics (NYSE:SENS) Stock Price Down 5% - Should You Sell?

Senseonics Holdings, Inc. (NYSE:SENS - Get Free Report)'s stock price dropped 5% on Wednesday . The stock traded as low as $1.04 and last traded at $1.06. Approximately 4,024,237 shares were traded during trading, a decline of 81% from the average daily volume of 21,064,957 shares. The stock had previously closed at $1.11.

Analysts Set New Price Targets

SENS has been the topic of several recent research reports. HC Wainwright reaffirmed a "buy" rating and issued a $2.00 price objective on shares of Senseonics in a report on Friday, November 15th. StockNews.com initiated coverage on shares of Senseonics in a research report on Thursday, December 26th. They set a "sell" rating on the stock.

Senseonics Stock Down 11.9 %

The business's 50-day simple moving average is $0.58 and its two-hundred day simple moving average is $0.44. The company has a debt-to-equity ratio of 59.17, a quick ratio of 2.38 and a current ratio of 2.47.

Senseonics (NYSE:SENS - Get Free Report) last issued its quarterly earnings results on Thursday, November 7th. The company reported ($0.04) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.03) by ($0.01). The firm had revenue of $4.26 million during the quarter, compared to analysts' expectations of $4.02 million. Senseonics had a negative return on equity of 842.25% and a negative net margin of 362.30%. As a group, equities research analysts predict that Senseonics Holdings, Inc. will post -0.14 earnings per share for the current fiscal year.

Remove Ads

Insider Buying and Selling at Senseonics

In other news, CFO Frederick T. Sullivan bought 124,933 shares of Senseonics stock in a transaction on Thursday, December 12th. The shares were bought at an average cost of $0.38 per share, for a total transaction of $47,474.54. Following the acquisition, the chief financial officer now owns 2,478,844 shares in the company, valued at approximately $941,960.72. This trade represents a 5.31 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO Timothy T. Goodnow acquired 315,000 shares of the business's stock in a transaction dated Tuesday, December 10th. The shares were bought at an average price of $0.31 per share, for a total transaction of $97,650.00. Following the completion of the acquisition, the chief executive officer now owns 11,310,355 shares in the company, valued at approximately $3,506,210.05. This trade represents a 2.86 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 3.60% of the stock is currently owned by corporate insiders.

Institutional Trading of Senseonics

A number of institutional investors and hedge funds have recently bought and sold shares of SENS. FMR LLC grew its position in shares of Senseonics by 48,267.2% during the third quarter. FMR LLC now owns 168,318 shares of the company's stock worth $59,000 after buying an additional 167,970 shares in the last quarter. Ridgecrest Wealth Partners LLC acquired a new position in Senseonics during the fourth quarter worth about $60,000. GSA Capital Partners LLP acquired a new position in Senseonics during the third quarter worth about $117,000. Symmetry Partners LLC purchased a new position in Senseonics in the 3rd quarter worth about $164,000. Finally, Cubist Systematic Strategies LLC increased its stake in Senseonics by 25.9% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 415,404 shares of the company's stock worth $166,000 after purchasing an additional 85,501 shares in the last quarter. Institutional investors and hedge funds own 12.36% of the company's stock.

Senseonics Company Profile

Senseonics Holdings, Inc, a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management.